



Xenon Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

November 10, 2014

BURNABY, British Columbia, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced initial public offering of 4,600,000 of its common shares at a price to the public of \$9.00 per share. The common shares sold include 600,000 common shares sold pursuant to the option to purchase additional shares granted by Xenon Pharmaceuticals to the underwriters, which was exercised in full.

Jefferies LLC and Wells Fargo Securities, LLC acted as joint book-running managers for the offering. Canaccord Genuity Inc. acted as co-manager.

A registration statement relating to this offering of common shares was declared effective by the Securities and Exchange Commission on November 4, 2014, and the offering was also qualified by a prospectus filed in each of British Columbia, Alberta and Ontario.

The offering of these securities was made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com; or Wells Fargo Securities, LLC, Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, or by telephone at (800) 326-5897, or by email at cmclientsupport@wellsfargo.com, and a Canadian prospectus, a copy of which may be obtained from Canaccord Genuity Corp. Attn: Syndication, 161 Bay Street, Suite 3000 Toronto, ON M5J 2S1, or by telephone at (416) 869-7398 or by email at ecm@canaccordgenuity.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

CONTACT: Xenon Pharmaceuticals Contact Information:

Ian Mortimer
Chief Financial Officer
Xenon Pharmaceuticals Inc.
Phone: 604.484.3300
Email: investors@xenon-pharma.com

[Xenon Pharmaceuticals Inc. Logo](#)

Xenon Pharmaceuticals Inc.